化疗联合热疗治疗中晚期胃癌有效性及安全性系统评价
|
摘要
目的化疗与热疗有协同抗癌作用,为确定热疗在胃癌综合治疗中的临床价值,本研究系统评价了化疗联合热疗治疗中晚期胃癌的有效性及安全性。方法计算机检索Cochrane Library、PubMed、EMBase和Web of Science等外文数据库,以及中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普中文科技期刊数据库(VIP)和万方数据知识服务平台(WanFang)等中文数据库,配合补充检索手段,收集所有比较联合疗法与单独化疗的随机对照试验(randomized controlled trial,RCT)。提取纳入文献资料,包括第一作者、发表时间、样本量、卡氏评分及结局指标等,并进行方法学质量评价。结果共纳入34篇RCT,合计3 018例患者。有效性评价:1(RR=1.13,95%CI为1.07~1.20)、2(RR=1.34,95%CI为1.20~1.50)、3(RR=1.32,95%CI为1.15~1.51)和5年(RR=1.63,95%CI为1.15~2.31)生存率以及完全缓解率(RR=1.90,95%CI为1.50~2.41)、总有效率(RR=1.53,95%CI为1.40~1.67)、生活质量改善率(RR=1.51,95%CI为1.32~1.74)及复发率(RR=0.68,95%CI为0.58~0.80)在联合组和单独化疗组间差异有统计学意义,均P<0.05;联合组的1、2、3和5年生存率以及完全缓解率、总有效率、生活质量改善率均高于单独化疗组,复发率低于单独化疗组。安全性评价:白细胞下降(RR=0.85,95%CI为0.78~0.92)、恶心呕吐(RR=0.80,95%CI为0.73~0.87)、腹痛(RR=0.56,95%CI为0.47~0.67)和腹泻(RR=0.70,95%CI为0.60~0.81)4个指标的发生率在2组间差异均有统计学意义,均P<0.05;联合组中的发生率均低于单独化疗组;手足综合征、脱发、周围神经毒性和肝肾功能损伤等指标发生率在2组间的差异均无统计学意义,均P>0.05。结论与单独化疗方案治疗中晚期胃癌相比,化疗与热疗的联合方案可提高长期生存率、改善近期疗效、降低患者的复发率,并且有利于降低化疗引起的毒副作用,但该结论尚需高质量的临床研究进一步证实。
OBJECTIVE There is synergistic anticancer action from combination of chemotherapy and thermotherapy.In order to determine the clinical value of thermotherapy in comprehensive treatment of the stomach cancer,this article systematically reviewed the efficacy and safety of chemotherapy combined with thermotherapy for advanced gastric cancer.METHODS A computer-based retrieval was performed in foreign databases as Cochrane Library,PubMed,EMbase,Web of Science and Chinese ones as CBM,CNKI,VIP and WanFang,and supplementary retrieval was also performed with other sources.All relevant randomized controlled trials(RCTs)were collected to compare combination therapy and chemotherapy alone.We extracted the relevant information from the literatures,including the first author,published time,sample size,karnofsky performance status and outcome indicators.Then we assessed the methodologic quality of included studies.RESULTS A total of 34 literatures were included,comprising 3 018 patients.Meta-analysis showed:there were all significant difference between the two groups at 1,2,3,5-year survival rate(RR=1.13,95%CI=1.07-1.20;RR=1.34,95%CI=1.20-1.50;RR=1.32,95%CI=1.15-1.51;RR=1.63,95%CI=1.15-2.31),complete remission rate(RR=1.90,95%CI=1.50-2.41),total effective rate(RR=1.53,95%CI=1.40-1.67),improving rate of life quality(RR=1.51,95%CI=1.32-1.74)and recurrence rate(RR=0.68,95%CI=0.58-0.80;P<0.05);the 1,2,3,5-year survival rate,complete remission rate,total effective rate and improving rate of life quality of combination group were superior to those of chemotherapy alone group,and the recurrence rate of combination group was lower than that of chemotherapy alone group.There were all significant differences between the two groups at the incidence of leukocytopenia(RR=0.85,95%CI=0.78-0.92),nausea and vomiting(RR=0.80,95%CI=0.73-0.87),and abdominal pain(RR=0.56,95%CI=0.47-0.67)and diarrhea(RR=0.70,95%CI=0.60,0.81;P<0.05),and these incidence of combination group were lower than those of chemotherapy alone group;but there were no significant differences between the two groups in the incidence of handfoot syndrome,alopecia,peripheral neurotoxicity,hepatic and kidney lesion(P>0.05).CONCLUSIONS Comparedwith chemotherapy alone,chemotherapy combined with thermotherapy for advanced gastric cancer can improve long-term survival rate and short-term curative effect,reduce recurrence rate;additionally,it presents a good clinical security,and is helpful to reduce the incidence of some adverse reaction.However,high quality clinical studies are needed to further confirm this conclusion.
OBJECTIVE There is synergistic anticancer action from combination of chemotherapy and thermotherapy.In order to determine the clinical value of thermotherapy in comprehensive treatment of the stomach cancer,this article systematically reviewed the efficacy and safety of chemotherapy combined with thermotherapy for advanced gastric cancer.METHODS A computer-based retrieval was performed in foreign databases as Cochrane Library,PubMed,EMbase,Web of Science and Chinese ones as CBM,CNKI,VIP and WanFang,and supplementary retrieval was also performed with other sources.All relevant randomized controlled trials(RCTs)were collected to compare combination therapy and chemotherapy alone.We extracted the relevant information from the literatures,including the first author,published time,sample size,karnofsky performance status and outcome indicators.Then we assessed the methodologic quality of included studies.RESULTS A total of 34 literatures were included,comprising 3 018 patients.Meta-analysis showed:there were all significant difference between the two groups at 1,2,3,5-year survival rate(RR=1.13,95%CI=1.07-1.20;RR=1.34,95%CI=1.20-1.50;RR=1.32,95%CI=1.15-1.51;RR=1.63,95%CI=1.15-2.31),complete remission rate(RR=1.90,95%CI=1.50-2.41),total effective rate(RR=1.53,95%CI=1.40-1.67),improving rate of life quality(RR=1.51,95%CI=1.32-1.74)and recurrence rate(RR=0.68,95%CI=0.58-0.80;P<0.05);the 1,2,3,5-year survival rate,complete remission rate,total effective rate and improving rate of life quality of combination group were superior to those of chemotherapy alone group,and the recurrence rate of combination group was lower than that of chemotherapy alone group.There were all significant differences between the two groups at the incidence of leukocytopenia(RR=0.85,95%CI=0.78-0.92),nausea and vomiting(RR=0.80,95%CI=0.73-0.87),and abdominal pain(RR=0.56,95%CI=0.47-0.67)and diarrhea(RR=0.70,95%CI=0.60,0.81;P<0.05),and these incidence of combination group were lower than those of chemotherapy alone group;but there were no significant differences between the two groups in the incidence of handfoot syndrome,alopecia,peripheral neurotoxicity,hepatic and kidney lesion(P>0.05).CONCLUSIONS Comparedwith chemotherapy alone,chemotherapy combined with thermotherapy for advanced gastric cancer can improve long-term survival rate and short-term curative effect,reduce recurrence rate;additionally,it presents a good clinical security,and is helpful to reduce the incidence of some adverse reaction.However,high quality clinical studies are needed to further confirm this conclusion.
引文
[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3]Mi DH,Li Z,Yang KH,et al.Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy(IHIC)for gastric cancer:a systematic review and meta-analysis of randomised controlled trials[J].Int J Hyperthermia,2013,29(2):156-167.
[4]李征,杨克虎,米登海,等.进展期胃癌术后腹腔热灌注化疗有效性和安全性的系统评价[J].中国循证医学杂志,2011,11(12):1402-1408.
[5]李征,米登海,杨克虎,等.胃癌术中联合术后腹腔热灌注化疗的Meta分析[J].实用肿瘤杂志,2012,27(6):636-642.
[6]Gill RS,Al-Adra DP,Nagendran J,et al.Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC:a systematic review of survival,mortality,and morbidity[J].J Surg Oncol,2011,104(6):692-698.
[7]邱健,李国威,王小强,等.胃癌根治术中预防性腹腔温热灌注化疗治疗进展期胃癌的系统评价[J].中国循证医学杂志,2004,4(12):859-863,894.
[8]吴印兵,巴明臣,崔书中,等.进展期胃癌腹腔热灌注化疗临床疗效与安全性Meta分析[J].中华肿瘤防治杂志,2013,20(21):1686-1690.
[9]冯莉,刘巍,洪雷,等.化疗联合局部热疗治疗晚期胃癌疗效与安全性的Meta分析[J].转化医学杂志,2014,3(2):84-87,95.
[10]Bull JM.Whole body hyperthermia as an anticancer agent[J].CA Cancer J Clin,1982,32(2):123-128.
[11]Storm FK,Morton DL.Localized hyperthermia in the treatment of cancer[J].CA Cancer J Clin,1983,33(1):44-56.
[12]Li Z,Mi DH,Yang KH,et al.Comparison between Autocad and Draftsight in data extraction[J].Cochrane Database Syst Rev,2013,2013(9Suppl):56.
[13]Li Z,Yang KH,Mi DH,et al.The method of exracting data from figure with software[J].Cochrane Database Syst Rev,2012,2012(9Suppl):104.
[14]Fujimura T,Yonemura Y,Muraoka K,et al.Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer:randomized controlled study[J].World J Surg,1994,18(1):150-155.
[15]Shido A,Ohmura S,Yamamoto K,et al.Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion?[J].World J Surg,2000,24(5):507-511.
[16]谭春祈,王心见,徐亚琨,等.术中热化疗预防进展期胃癌腹腔种植转移的研究[J].实用肿瘤杂志,2000,15(3):165-168.
[17]Yonemura Y,de Aretxabala X,Fujimura T,et al.Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer:final results of a randomized controlled study[J].Hepatogastroenterology,2001,48(42):1776-1782.
[18]郑鸿,李勇,房定珠,等.热疗联用FOLFOX化疗方案治疗21例晚期胃癌[J].中国癌症杂志,2006,16(7):581-583.
[19]林显敢,黄开红,谢德荣,等.进展期胃癌术后腹部内生场热疗联合FOLFOX方案的疗效分析:附68例报道[J].南方医科大学学报,2007,27(10):1501-1503.
[20]王芳,肖菁,金建华.深部热疗联合紫杉醇每周疗法治疗晚期胃癌的临床观察[J].中国现代医药杂志,2009,11(3):65-66.
[21]杜才聚,王同林,郭银素.中药结合化疗及热疗改善晚期胃癌生存质量临床观察[J].河北中医,2010,32(9):1299-1301.
[22]郭建峰,张存良,张向淼,等.热疗联合化疗治疗晚期胃癌的疗效观察[J].中国现代医生,2010,48(9):101-102,131.
[23]李贵新,路中,孙秀梅,等.腹部射频热疗联合化疗治疗Ⅳ期胃癌的近期疗效观察[J].中华肿瘤防治杂志,2010,17(7):526-528.
[24]夏春芳,潘友兰,黎静,等.腹腔灌注和全身热疗治疗非根治术后晚期胃癌56例临床分析[J].中国现代医学杂志,2010,20(3):461-463,466.
[25]沈清,金赟洁,朱纪华,等.内生场热化疗对胃癌转移性腹腔淋巴结的疗效及血清肿瘤标志物的影响[J].肿瘤,2011,31(9):859-862.
[26]徐学新,张炜,温爱萍.康莱特腹腔热灌注联合FORFOX4方案治疗进展期胃癌的临床观察[J].湖南中医药大学学报,2011,31(12):18-20.
[27]蔡晓军,邓守恒,潘东风,等.替吉奥联合奥沙利铂化疗及热疗治疗晚期胃癌的临床研究[J].现代中西医结合杂志,2012,21(29):3237-3238.
[28]廖国清,曲怡梅,王红梅,等.循环热灌注化疗治疗晚期胃癌合并腹腔积液的临床研究[J].中国肿瘤临床,2012,39(8):452-454.
[29]吕雅蕾,刘会芝,翟宝娥,等.全身化疗联合局部热疗治疗晚期胃癌的临床观察[J].肿瘤学杂志,2012,18(2):121-123.
[30]安贞兰,章岳山,张叶萍,等.替吉奥联合腹腔灌注顺铂、香菇多糖及热疗对晚期胃癌合并癌性腹水的疗效观察[J/CD].中华临床医师杂志:电子版,2013,7(19):8951-8953.
[31]白云飞,刘东莲,萨日娜,等.可切除进展期胃癌术后热疗联合化疗效果观察[J].人民军医,2013,56(5):540-542.
[32]丁纪元,李俊,寇军燕,等.SOX方案联合腹部热疗治疗晚期胃癌的临床观察[J].中国农村卫生事业管理,2013,33(5):599-600.
[33]张立新,孙芳初,孙国贵,等.顺铂联合腹腔持续热灌注治疗胃癌腹腔转移癌性腹水的临床研究[J].中国肿瘤,2013,22(5):413-416.
[34]朱利楠,樊青霞,宗红,等.热疗联合化疗在晚期胃癌中的临床应用[J].中华物理医学与康复杂志,2013,35(4):326-329.
[35]卢庆刚,牟安娜,朱礼,等.局部热疗联合奥沙利铂、多西紫杉醇、5-氟尿嘧啶治疗晚期胃癌的临床随访研究[J].疑难病杂志,2014,13(6):597-600.
[36]吕行,张进儒,宁鹏,等.紫杉醇联合顺铂腹腔热灌注化疗对胃癌恶性腹腔积液疗效的临床研究[J/CD].中国医学前沿杂志:电子版,2014,6(10):126-128.
[37]陶洪,伍显庭,付江萍.循环热灌注化疗治疗晚期胃癌合并腹腔积液的临床研究[J].疑难病杂志,2014,13(11):1146-1148.
[38]王保庆,张世强,薛青萍,等.全身热疗联合化疗治疗晚期胃癌的疗效分析[J].肿瘤基础与临床,2014,27(5):392-394.
[39]王小文,谢金龙,李伟,等.热疗联合化疗治疗晚期胃癌患者的疗效和安全性研究[J].中国临床实用医学,2014,5(4):27-29.
[40]袁鹏,岳天华,肖艳华,等.腹腔热灌注化疗治疗胃癌恶性腹水的临床疗效[J].世界华人消化杂志,2014,22(31):4825-4829.
[41]耿炜,曹海英,张建宇,等.全身热疗联合XELOX化疗方案应用于晚期胃癌疗效观察[J].中国现代医生,2015,53(28):34-36,40,161.
[42]胡娜,梁家铭,苏莹莹,等.老年胃癌腹腔热灌注化疗联合静脉化疗治疗恶性腹水的临床疗效[J].中国老年学杂志,2015,35(16):4578-4579.
[43]李娜,李勇,巩平,等.热疗联合替吉奥治疗老年晚期胃癌的临床疗效[J].世界华人消化杂志,2015,23(3):445-450.
[44]唐滟,邓力红.DP方案双路径化疗联合全身热疗治疗晚期胃癌并恶性腹腔积液临床观察[J].中国现代医学杂志,2015,25(34):94-96.
[45]严京哲,马英桓,李东文.腹腔热化疗治疗胃癌性腹水的疗效研究[J].临床军医杂志,2015,43(7):729-732.
[46]张志影,徐海燕,陈彬,等.肿瘤深部热化疗对复发转移胃癌生存期的影响及其预测因素[J].世界华人消化杂志,2015,23(3):438-444.
[47]陈红娜,王海增.替吉奥联合奥沙利铂配合局部电容场深部热疗治疗晚期胃癌的临床应用[J].中国实用医药,2016,11(1):205-206.
[48]李雁,周云峰,梁寒,等.细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识[J].中国肿瘤临床,2015,42(4):198-206.
[49]李征,米登海,杨克虎,等.腹腔热灌注化疗治疗癌性腹水的系统评价[J].中国普通外科杂志,2014,23(8):1106-1111.
[50]Knippertz I,Stein MF,Dorrie J,et al.Mild hyperthermia enhances human monocyte-derived dendritic cell functions and offers potential for applications in vaccination strategies[J].Int J Hyperthermia,2011,27(6):591-603.
[51]Frey B,Weiss EM,Rubner Y,et al.Old and new facts about hyperthermia-induced modulations of the immune system[J].Int J Hyperthermia,2012,28(6):528-542.
[52]Mace TA,Zhong L,Kokolus KM,et al.Effector CD8+T cell IFN-gamma production and cytotoxicity are enhanced by mild hyperthermia[J].Int J Hyperthermia,2012,28(1):9-18.
[53]米登海,李征,杨克虎,等.GP或TP化疗联合热疗治疗非小细胞肺癌的系统评价[J].中国肺癌杂志,2012,15(8):456-464.
[54]李征,米登海,杨克虎,等.化疗联合热疗治疗食管癌的Meta分析[J].中华肿瘤防治杂志,2013,20(1):61-66.
[55]颉宝平,李征,姚南,等.化疗联合热疗治疗晚期大肠癌疗效及安全性的Meta分析[J].中国循证医学杂志,2013,13(3):352-357.
[56]Li Z,Yang KH,Mi DH,et al.The research about guidance of systematic review for clinical study[J].Cochrane Database Syst Rev,2012,2012(9Suppl):107.
[57]van der Zee J.Heating the patient:apromising approach?[J].Ann Oncol,2002,13(8):1173-1184.
[58]Bruggmoser G,Bauchowitz S,Canters R,et al.Quality assurance for clinical studies in regional deep hyperthermia[J].Strahlenther Onkol,2011,187(10):605-610.
[2]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3]Mi DH,Li Z,Yang KH,et al.Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy(IHIC)for gastric cancer:a systematic review and meta-analysis of randomised controlled trials[J].Int J Hyperthermia,2013,29(2):156-167.
[4]李征,杨克虎,米登海,等.进展期胃癌术后腹腔热灌注化疗有效性和安全性的系统评价[J].中国循证医学杂志,2011,11(12):1402-1408.
[5]李征,米登海,杨克虎,等.胃癌术中联合术后腹腔热灌注化疗的Meta分析[J].实用肿瘤杂志,2012,27(6):636-642.
[6]Gill RS,Al-Adra DP,Nagendran J,et al.Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC:a systematic review of survival,mortality,and morbidity[J].J Surg Oncol,2011,104(6):692-698.
[7]邱健,李国威,王小强,等.胃癌根治术中预防性腹腔温热灌注化疗治疗进展期胃癌的系统评价[J].中国循证医学杂志,2004,4(12):859-863,894.
[8]吴印兵,巴明臣,崔书中,等.进展期胃癌腹腔热灌注化疗临床疗效与安全性Meta分析[J].中华肿瘤防治杂志,2013,20(21):1686-1690.
[9]冯莉,刘巍,洪雷,等.化疗联合局部热疗治疗晚期胃癌疗效与安全性的Meta分析[J].转化医学杂志,2014,3(2):84-87,95.
[10]Bull JM.Whole body hyperthermia as an anticancer agent[J].CA Cancer J Clin,1982,32(2):123-128.
[11]Storm FK,Morton DL.Localized hyperthermia in the treatment of cancer[J].CA Cancer J Clin,1983,33(1):44-56.
[12]Li Z,Mi DH,Yang KH,et al.Comparison between Autocad and Draftsight in data extraction[J].Cochrane Database Syst Rev,2013,2013(9Suppl):56.
[13]Li Z,Yang KH,Mi DH,et al.The method of exracting data from figure with software[J].Cochrane Database Syst Rev,2012,2012(9Suppl):104.
[14]Fujimura T,Yonemura Y,Muraoka K,et al.Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer:randomized controlled study[J].World J Surg,1994,18(1):150-155.
[15]Shido A,Ohmura S,Yamamoto K,et al.Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion?[J].World J Surg,2000,24(5):507-511.
[16]谭春祈,王心见,徐亚琨,等.术中热化疗预防进展期胃癌腹腔种植转移的研究[J].实用肿瘤杂志,2000,15(3):165-168.
[17]Yonemura Y,de Aretxabala X,Fujimura T,et al.Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer:final results of a randomized controlled study[J].Hepatogastroenterology,2001,48(42):1776-1782.
[18]郑鸿,李勇,房定珠,等.热疗联用FOLFOX化疗方案治疗21例晚期胃癌[J].中国癌症杂志,2006,16(7):581-583.
[19]林显敢,黄开红,谢德荣,等.进展期胃癌术后腹部内生场热疗联合FOLFOX方案的疗效分析:附68例报道[J].南方医科大学学报,2007,27(10):1501-1503.
[20]王芳,肖菁,金建华.深部热疗联合紫杉醇每周疗法治疗晚期胃癌的临床观察[J].中国现代医药杂志,2009,11(3):65-66.
[21]杜才聚,王同林,郭银素.中药结合化疗及热疗改善晚期胃癌生存质量临床观察[J].河北中医,2010,32(9):1299-1301.
[22]郭建峰,张存良,张向淼,等.热疗联合化疗治疗晚期胃癌的疗效观察[J].中国现代医生,2010,48(9):101-102,131.
[23]李贵新,路中,孙秀梅,等.腹部射频热疗联合化疗治疗Ⅳ期胃癌的近期疗效观察[J].中华肿瘤防治杂志,2010,17(7):526-528.
[24]夏春芳,潘友兰,黎静,等.腹腔灌注和全身热疗治疗非根治术后晚期胃癌56例临床分析[J].中国现代医学杂志,2010,20(3):461-463,466.
[25]沈清,金赟洁,朱纪华,等.内生场热化疗对胃癌转移性腹腔淋巴结的疗效及血清肿瘤标志物的影响[J].肿瘤,2011,31(9):859-862.
[26]徐学新,张炜,温爱萍.康莱特腹腔热灌注联合FORFOX4方案治疗进展期胃癌的临床观察[J].湖南中医药大学学报,2011,31(12):18-20.
[27]蔡晓军,邓守恒,潘东风,等.替吉奥联合奥沙利铂化疗及热疗治疗晚期胃癌的临床研究[J].现代中西医结合杂志,2012,21(29):3237-3238.
[28]廖国清,曲怡梅,王红梅,等.循环热灌注化疗治疗晚期胃癌合并腹腔积液的临床研究[J].中国肿瘤临床,2012,39(8):452-454.
[29]吕雅蕾,刘会芝,翟宝娥,等.全身化疗联合局部热疗治疗晚期胃癌的临床观察[J].肿瘤学杂志,2012,18(2):121-123.
[30]安贞兰,章岳山,张叶萍,等.替吉奥联合腹腔灌注顺铂、香菇多糖及热疗对晚期胃癌合并癌性腹水的疗效观察[J/CD].中华临床医师杂志:电子版,2013,7(19):8951-8953.
[31]白云飞,刘东莲,萨日娜,等.可切除进展期胃癌术后热疗联合化疗效果观察[J].人民军医,2013,56(5):540-542.
[32]丁纪元,李俊,寇军燕,等.SOX方案联合腹部热疗治疗晚期胃癌的临床观察[J].中国农村卫生事业管理,2013,33(5):599-600.
[33]张立新,孙芳初,孙国贵,等.顺铂联合腹腔持续热灌注治疗胃癌腹腔转移癌性腹水的临床研究[J].中国肿瘤,2013,22(5):413-416.
[34]朱利楠,樊青霞,宗红,等.热疗联合化疗在晚期胃癌中的临床应用[J].中华物理医学与康复杂志,2013,35(4):326-329.
[35]卢庆刚,牟安娜,朱礼,等.局部热疗联合奥沙利铂、多西紫杉醇、5-氟尿嘧啶治疗晚期胃癌的临床随访研究[J].疑难病杂志,2014,13(6):597-600.
[36]吕行,张进儒,宁鹏,等.紫杉醇联合顺铂腹腔热灌注化疗对胃癌恶性腹腔积液疗效的临床研究[J/CD].中国医学前沿杂志:电子版,2014,6(10):126-128.
[37]陶洪,伍显庭,付江萍.循环热灌注化疗治疗晚期胃癌合并腹腔积液的临床研究[J].疑难病杂志,2014,13(11):1146-1148.
[38]王保庆,张世强,薛青萍,等.全身热疗联合化疗治疗晚期胃癌的疗效分析[J].肿瘤基础与临床,2014,27(5):392-394.
[39]王小文,谢金龙,李伟,等.热疗联合化疗治疗晚期胃癌患者的疗效和安全性研究[J].中国临床实用医学,2014,5(4):27-29.
[40]袁鹏,岳天华,肖艳华,等.腹腔热灌注化疗治疗胃癌恶性腹水的临床疗效[J].世界华人消化杂志,2014,22(31):4825-4829.
[41]耿炜,曹海英,张建宇,等.全身热疗联合XELOX化疗方案应用于晚期胃癌疗效观察[J].中国现代医生,2015,53(28):34-36,40,161.
[42]胡娜,梁家铭,苏莹莹,等.老年胃癌腹腔热灌注化疗联合静脉化疗治疗恶性腹水的临床疗效[J].中国老年学杂志,2015,35(16):4578-4579.
[43]李娜,李勇,巩平,等.热疗联合替吉奥治疗老年晚期胃癌的临床疗效[J].世界华人消化杂志,2015,23(3):445-450.
[44]唐滟,邓力红.DP方案双路径化疗联合全身热疗治疗晚期胃癌并恶性腹腔积液临床观察[J].中国现代医学杂志,2015,25(34):94-96.
[45]严京哲,马英桓,李东文.腹腔热化疗治疗胃癌性腹水的疗效研究[J].临床军医杂志,2015,43(7):729-732.
[46]张志影,徐海燕,陈彬,等.肿瘤深部热化疗对复发转移胃癌生存期的影响及其预测因素[J].世界华人消化杂志,2015,23(3):438-444.
[47]陈红娜,王海增.替吉奥联合奥沙利铂配合局部电容场深部热疗治疗晚期胃癌的临床应用[J].中国实用医药,2016,11(1):205-206.
[48]李雁,周云峰,梁寒,等.细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识[J].中国肿瘤临床,2015,42(4):198-206.
[49]李征,米登海,杨克虎,等.腹腔热灌注化疗治疗癌性腹水的系统评价[J].中国普通外科杂志,2014,23(8):1106-1111.
[50]Knippertz I,Stein MF,Dorrie J,et al.Mild hyperthermia enhances human monocyte-derived dendritic cell functions and offers potential for applications in vaccination strategies[J].Int J Hyperthermia,2011,27(6):591-603.
[51]Frey B,Weiss EM,Rubner Y,et al.Old and new facts about hyperthermia-induced modulations of the immune system[J].Int J Hyperthermia,2012,28(6):528-542.
[52]Mace TA,Zhong L,Kokolus KM,et al.Effector CD8+T cell IFN-gamma production and cytotoxicity are enhanced by mild hyperthermia[J].Int J Hyperthermia,2012,28(1):9-18.
[53]米登海,李征,杨克虎,等.GP或TP化疗联合热疗治疗非小细胞肺癌的系统评价[J].中国肺癌杂志,2012,15(8):456-464.
[54]李征,米登海,杨克虎,等.化疗联合热疗治疗食管癌的Meta分析[J].中华肿瘤防治杂志,2013,20(1):61-66.
[55]颉宝平,李征,姚南,等.化疗联合热疗治疗晚期大肠癌疗效及安全性的Meta分析[J].中国循证医学杂志,2013,13(3):352-357.
[56]Li Z,Yang KH,Mi DH,et al.The research about guidance of systematic review for clinical study[J].Cochrane Database Syst Rev,2012,2012(9Suppl):107.
[57]van der Zee J.Heating the patient:apromising approach?[J].Ann Oncol,2002,13(8):1173-1184.
[58]Bruggmoser G,Bauchowitz S,Canters R,et al.Quality assurance for clinical studies in regional deep hyperthermia[J].Strahlenther Onkol,2011,187(10):605-610.